Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.

CONCLUSIONS: Prexasertib demonstrated an acceptable safety profile and single-agent activity in patients with advanced SCC. The prexasertib maximum-tolerated dose of 105 mg/m2 was confirmed as the recommended Phase II dose.
PMID: 29643063 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 11, 2018 Category: Cancer & Oncology Authors: Hong DS, Moore KN, Patel MR, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana SR, P Beckmann R, Bence Lin A, Eng C, Bendell JC Tags: Clin Cancer Res Source Type: research